@inproceedings{AbendscheinDesaiAstell2023,
  author    = {Abendschein, Robin and Desai, Shital and Astell, Arlene J.},
  title     = {Towards Accessibility Guidelines for the Metaverse : A Synthesis of Recommendations for People Living With Dementia},
  series = {Conference on Human Factors in Computing Systems (CHI'23) : Workshop "Towards an Inclusive and Accessible Metaverse"},
  booktitle = {Conference on Human Factors in Computing Systems (CHI'23) : Workshop "Towards an Inclusive and Accessible Metaverse"},
  doi       = {10.25972/OPUS-32019},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-320199},
  pages     = {6},
  year      = {2023},
  abstract  = {Given the growing interest of corporate stakeholders in Metaverse applications, there is a need to understand accessibility of these technologies for marginalized populations such as people living with dementia to ensure inclusive design of Metaverse applications. We assessed the accessibility of extended reality technology for people living with mild cognitive impairment and dementia to develop accessibility guidelines for these technologies. We used four strategies to synthesize evidence for barriers and facilitators of accessibility: (1) Findings from a non-systematic literature review, (2) guidelines from well-researched technology, (3) exploration of selected mixed reality technologies, and (4) observations from four sessions and video data of people living with dementia using mixed reality technologies. We utilized template analysis to develop codes and themes towards accessibility guidelines. Future work can validate our preliminary findings by applying them on video recordings or testing them in experiments.},
  subject      = {CHI Conference},
  language  = {en}
}
@article{TraubFreyStoerk2023,
  author    = {Traub, Jan and Frey, Anna and St{\"o}rk, Stefan},
  title     = {Chronic neuroinflammation and cognitive decline in patients with cardiac disease: evidence, relevance, and therapeutic implications},
  series = {Life},
  volume    = {13},
  journal   = {Life},
  number    = {2},
  issn      = {2075-1729},
  doi       = {10.3390/life13020329},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304869},
  year      = {2023},
  abstract  = {Acute and chronic cardiac disorders predispose to alterations in cognitive performance, ranging from mild cognitive impairment to overt dementia. Although this association is well-established, the factors inducing and accelerating cognitive decline beyond ageing and the intricate causal pathways and multilateral interdependencies involved remain poorly understood. Dysregulated and persistent inflammatory processes have been implicated as potentially causal mediators of the adverse consequences on brain function in patients with cardiac disease. Recent advances in positron emission tomography disclosed an enhanced level of neuroinflammation of cortical and subcortical brain regions as an important correlate of altered cognition in these patients. In preclinical and clinical investigations, the thereby involved domains and cell types of the brain are gradually better characterized. Microglia, resident myeloid cells of the central nervous system, appear to be of particular importance, as they are extremely sensitive to even subtle pathological alterations affecting their complex interplay with neighboring astrocytes, oligodendrocytes, infiltrating myeloid cells, and lymphocytes. Here, we review the current evidence linking cognitive impairment and chronic neuroinflammation in patients with various selected cardiac disorders including the aspect of chronic neuroinflammation as a potentially druggable target.},
  language  = {en}
}
@article{FriedrichHartigPruessetal.2022,
  author    = {Friedrich, Maximilian and Hartig, Johannes and Pr{\"u}ss, Harald and Ip, Wang Chi and Volkmann, Jens},
  title     = {Rapidly progressive dementia: Extending the spectrum of GFAP-astrocytopathies?},
  series = {Annals of Clinical and Translational Neurology},
  volume    = {9},
  journal   = {Annals of Clinical and Translational Neurology},
  number    = {3},
  doi       = {10.1002/acn3.51513},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312957},
  pages     = {410-415},
  year      = {2022},
  abstract  = {Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a steroid-responsive meningoencephalomyelitis, sometimes presenting with atypical clinical signs such as movement disorders or psychiatric and autonomic features. Beyond clinical presentation and imaging, diagnosis relies on detection of GFAP-antibodies (AB) in CSF. Using quantitative behavioral, serologic, and immunohistochemical analyses, we characterize two patients longitudinally over 18-24 months who presented with rapidly progressive neurocognitive deterioration in the context of GFAP-AB in CSF and unremarkable cranial MRI studies. Intensified immunotherapy was associated with clinical stabilization. The value of GFAP-AB screening in selected cases of rapidly progressive dementias is discussed.},
  language  = {en}
}
@article{HaberstumpfLeinweberLaueretal.2022,
  author    = {Haberstumpf, Sophia and Leinweber, Jonas and Lauer, Martin and Polak, Thomas and Deckert, J{\"u}rgen and Herrmann, Martin J.},
  title     = {Factors associated with dropout in the longitudinal Vogel study of cognitive decline},
  series = {The European Journal of Neuroscience},
  volume    = {56},
  journal   = {The European Journal of Neuroscience},
  number    = {9},
  doi       = {10.1111/ejn.15446},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-318945},
  pages     = {5587 -- 5600},
  year      = {2022},
  abstract  = {Dementia, including Alzheimer's disease, is a growing problem worldwide. Prevention or early detection of the disease or a prodromal cognitive decline is necessary. By means of our long-term follow-up 'Vogel study', we aim to predict the pathological cognitive decline of a German cohort (mean age was 73.9 ± 1.55 years at first visit) with three measurement time points within 6 years per participant. Especially in samples of the elderly and subjects with chronic or co-morbid diseases, dropouts are one of the biggest problems of long-term studies. In contrast to the large number of research articles conducted on the course of dementia, little research has been done on the completion of treatment. To ensure unbiased and reliable predictors of cognitive decline from study completers, our objective was to determine predictors of dropout. We conducted multivariate analyses of covariance and multinomial logistic regression analyses to compare and predict the subject's dropout behaviour at the second visit 3 years after baseline (full participation, partial participation and no participation/dropout) with neuropsychiatric, cognitive, blood and lifestyle variables. Lower performance in declarative memory, attention and visual-spatial processing predicted dropout rather than full participation. Lower performance in visual-spatial processing predicted partial participation as opposed to full participation. Furthermore, lower performance in mini-mental status examination predicted whether subjects dropped out or participated partially instead of full participation. Baseline cognitive parameters are associated with dropouts at follow-up with a loss of impaired participants. We expect a bias into a healthier sample over time.},
  language  = {en}
}
@article{BrumbergSchroeterBlazhenetsetal.2020,
  author    = {Brumberg, Joachim and Schr{\"o}ter, Nils and Blazhenets, Ganna and Frings, Lars and Volkmann, Jens and Lapa, Constantin and Jost, Wolfgang H. and Isaias, Ioannis U. and Meyer, Philipp T.},
  title     = {Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy},
  series = {NPJ Parkinsons Disease},
  volume    = {6},
  journal   = {NPJ Parkinsons Disease},
  doi       = {10.1038/s41531-020-00141-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-230675},
  year      = {2020},
  abstract  = {[\(^{18}\)F]fluorodeoxyglucose (FDG) PET and [\(^{123}\)I]metaiodobenzylguanidine (MIBG) scintigraphy may contribute to the differential diagnosis of neurodegenerative parkinsonism. To identify the superior method, we retrospectively evaluated 54 patients with suspected neurodegenerative parkinsonism, who were referred for FDG PET and MIBG scintigraphy. Two investigators visually assessed FDG PET scans using an ordinal 6-step score for disease-specific patterns of Lewy body diseases (LBD) or atypical parkinsonism (APS) and assigned the latter to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome. Regions-of-interest analysis on anterior planar MIBG images served to calculate the heart-to-mediastinum ratio. Movement disorder specialists blinded to imaging results established clinical follow-up diagnosis by means of guideline-derived case vignettes. Clinical follow-up (1.7 +/- 2.3 years) revealed the following diagnoses: n = 19 LBD (n = 17 Parkinson's disease [PD], n = 1 PD dementia, and n = 1 dementia with Lewy bodies), n = 31 APS (n = 28 MSA, n = 3 PSP), n = 3 non-neurodegenerative parkinsonism; n = 1 patient could not be diagnosed and was excluded. Receiver operating characteristic analyses for discriminating LBD vs. non-LBD revealed a larger area under the curve for FDG PET than for MIBG scintigraphy at statistical trend level for consensus rating (0.82 vs. 0.69, p = 0.06; significant for investigator \#1: 0.83 vs. 0.69, p = 0.04). The analysis of PD vs. MSA showed a similar difference (0.82 vs. 0.69, p = 0.11; rater \#1: 0.83 vs. 0.69, p = 0.07). Albeit the notable differences in diagnostic performance did not attain statistical significance, the authors consider this finding clinically relevant and suggest that FDG PET, which also allows for subgrouping of APS, should be preferred.},
  language  = {en}
}
@article{PetruskiIvlevaKucharskaNewtonPaltaetal.2017,
  author    = {Petruski-Ivleva, Natalia and Kucharska-Newton, Anna and Palta, Priya and Couper, David and Meyer, Katie and Graff, Misa and Haring, Bernhard and Sharrett, Richey and Heiss, Gerardo},
  title     = {Milk intake at midlife and cognitive decline over 20 years. The Atherosclerosis risk in communities (ARIC) study},
  series = {Nutrients},
  volume    = {9},
  journal   = {Nutrients},
  number    = {10},
  doi       = {10.3390/nu9101134},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173909},
  year      = {2017},
  abstract  = {Background: Faster rates of cognitive decline are likely to result in earlier onset of cognitive impairment and dementia. d-galactose, a derivative of lactose, is used in animal studies to induce neurodegeneration. Milk is the primary source of lactose in the human diet, and its effects on cognitive decline have not been fully evaluated. Objective: Assess the association of milk intake with change in cognitive function over 20 years. Methods: A total of 13,751 participants of the Atherosclerosis Risk in Communities (ARIC) cohort completed a food frequency questionnaire and three neurocognitive evaluations from 1990 through 2013. Two single nucleotide polymorphisms (SNPs) were used to determine lactase persistence (LCT-13910 C/T for Whites and LCT-14010 G/C for Blacks). Mixed-effects models were used to study the association of milk intake with cognitive change. Multiple imputations by chained equations were used to account for attrition. Results: Milk intake greater than 1 glass/day was associated with greater decline in the global z-score over a 20-year period. The difference in decline was 0.10 (95\% CI: 0.16, 0.03) z-scores, or an additional 10\% decline, relative to the group reporting "almost never" consuming milk. Conclusions: Replication of these results is warranted in diverse populations with greater milk intake and higher variability of lactase persistence genotype.},
  language  = {en}
}
@article{GalimbertiDell'OssoFenoglioetal.2012,
  author    = {Galimberti, Daniela and Dell'Osso, Bernardo and Fenoglio, Chiara and Villa, Chiara and Cortini, Francesca and Serpente, Maria and Kittel-Schneider, Sarah and Weigl, Johannes and Neuner, Maria and Volkert, Juliane and Leonhard, C. and Olmes, David G. and Kopf, Juliane and Cantoni, Claudia and Ridolfi, Elisa and Palazzo, Carlotta and Ghezzi, Laura and Bresolin, Nereo and Altamura, A.C. and Scarpini, Elio and Reif, Andreas},
  title     = {Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {4},
  doi       = {10.1371/journal.pone.0032164},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131910},
  pages     = {e32164},
  year      = {2012},
  abstract  = {Basing on the assumption that frontotemporal lobar degeneration (FTLD), schizophrenia and bipolar disorder (BPD) might share common aetiological mechanisms, we analyzed genetic variation in the FTLD risk gene progranulin (GRN) in a German population of patients with schizophrenia (n=271) or BPD (n=237) as compared with 574 age-, gender-and ethnicity-matched controls. Furthermore, we measured plasma progranulin levels in 26 German BPD patients as well as in 61 Italian BPD patients and 29 matched controls. A significantly decreased allelic frequency of the minor versus the wild-type allele was observed for rs2879096 (23.2 versus 34.2\%, P<0.001, OR: 0.63, 95\% CI: 0.49-0.80), rs4792938 (30.7 versus 39.7\%, P=0.005, OR: 0.70, 95\% CI: 0.55-0.89) and rs5848 (30.3 versus 36.8, P=0.007, OR: 0.71, 95\% CI: 0.56-0.91). Mean +/- SEM progranulin plasma levels were significantly decreased in BPD patients, either Germans or Italians, as compared with controls (89.69 +/- 3.97 and 116.14 +/- 5.80 ng/ml, respectively, versus 180.81 +/- 18.39 ng/ml P<0.001) and were not correlated with age. In conclusion, GRN variability decreases the risk to develop BPD and schizophrenia, and progranulin plasma levels are significantly lower in BPD patients than in controls. Nevertheless, a larger replication analysis would be needed to confirm these preliminary results.},
  language  = {en}
}
@phdthesis{Schmid2012,
  author    = {Schmid, Benedikt},
  title     = {Relation between cerebral arterio-venous transit time and neuropsychological performance in patients with vascular dementia},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-71234},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Dementia, or any form of degenerative cognitive decline, is one of the major problems in present, and even more will be in future medicine. With Alzheimer's disease (AD) being the most prevalent, Vascular Dementia is the second most entity of dementing processes in the elderly. As diagnostic criteria are still imprecise and in many cases do not embrace early stages of the disease, recent studies have proposed more detailed classifications of the newly created condition Vascular Cognitive Impairment (VCI). Of all conditions subsumed under this term, subcortical small-vessel alterations are the most common cause for cognitive decline. The diagnosis of dementia / cognitive impairment is presently often made in late stages of the disease, when therapeutical options are poor. Thus, early detection of changes of the subcortical small vessels is desirable, when there is still time to identify and aggressively treat risk factors and underlying conditions like diabetes, hyper- or hypotension, and hyperlipidemia. This study aimed to evaluate whether cTT correlates to cognitive dysfunction, i.e. if cTT is fit as an early diagnostic tool for VCI. The study cohort included 38 patients from the Neurological Clinic of the W{\"u}rzburg University hospital admitted due to diagnoses other than dementia or stroke. As a result of this study it turned out that cTT is certainly capable of fulfilling the task to easily and effectively detect and evaluate possible microvascular lesions of the brain with respect to the actual clinical relevance for the patient. When compared to the other proposed diagnostic tools, neuropsychological testing and MRI, the advantages of cTT are obvious: its measurement is a low-cost and quick procedure which would spare both patients and examiners a long neuropsychological exam or complement it. cTT is safe to assess as the only possible risks derive from the use of the contrast agent, which are rare and easily manageable. It has also proven to be more accurate in showing the extent of cognitive impairment than MRI. Finally, it is widely available. The only prerequisite is an ultrasound machine capable of transcranial color-coded duplex sonography. No cost-intensive procedures like MRI are needed. So, with neuropsychological testing remaining the gold standard, cTT here proved to be a reliable alternative which is more time- and cost-effective than MRI.},
  subject      = {Demenz},
  language  = {en}
}